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Background
Adverse event (AE) reporting is an integral part of safety
monitoring for clinical trials and standard definitions for
medical AEs exist under GCP. However, public health
trials in community settings present challenges for con-
sistent safety monitoring. For studies of complex beha-
viour change interventions, what should be recorded
may not be self-evident. Building Blocks is such a trial
and is evaluating the effectiveness of a home visiting
intervention (Family Nurse Partnership programme).
This presentation aims to assess variability in safety
reporting, and explore factors associated with nature,
level and quality of reporting.
Methods
1,645 first-time mothers aged 19 or under were recruited
across 18 sites. SAEs were reported during the 2.5 year
follow-up period. All SAE forms were reviewed and cate-
gorised by an independent rater as either medical SAEs
or AEs (standard GCP definition), or non-medical SAEs
(using emergent study-specific definitions).
Results
Over 1700 AE forms were returned. Reporting rates
(reports per participants per site) varied considerably by
site (22% to 465%). The results of the categorising exer-
cise is to follow, and exploration of factors predictive of
SAE reporting will be reported (e.g. site, participant,
researcher).
Conclusions
In all trials AEs may occur and require a robust moni-
toring process. The nature of non-medical AEs may be
especially important in some trials. Researchers need to
understand what may be relevant and ensure consistent
and valid reporting. Such information will guide trial
management (e.g. alert interviewers prior to follow-up
assessments), and ensure harmful effects potentially
attributable to the intervention are monitored.
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